296 related articles for article (PubMed ID: 26897942)
21. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
[TBL] [Abstract][Full Text] [Related]
22. Time-dependency of the prognostic effect of carcinoembryonic antigen and p53 protein in colorectal adenocarcinoma.
Diez M; Pollan M; Müguerza JM; Gaspar MJ; Duce AM; Alvarez MJ; Ratia T; Herñandez P; Ruiz A; Granell J
Cancer; 2000 Jan; 88(1):35-41. PubMed ID: 10618603
[TBL] [Abstract][Full Text] [Related]
23. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
[TBL] [Abstract][Full Text] [Related]
24. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.
Ochiai H; Ohishi T; Osumi K; Tokuyama J; Urakami H; Seki S; Shimada A; Matsui A; Isobe Y; Murata Y; Endo T; Ishii Y; Hasegawa H; Matsumoto S; Kitagawa Y
Surg Today; 2012 Jan; 42(2):164-8. PubMed ID: 22075664
[TBL] [Abstract][Full Text] [Related]
25. Comparative analysis of tumor markers and evaluation of their predictive value in patients with colorectal cancer.
Liu ZP; Li LM; Liu XL; Zhang DX
Onkologie; 2012; 35(3):108-13. PubMed ID: 22414974
[TBL] [Abstract][Full Text] [Related]
26. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
27. Inflammation-based prognostic system predicts postoperative survival of colorectal cancer patients with a normal preoperative serum level of carcinoembryonic antigen.
Ishizuka M; Nagata H; Takagi K; Iwasaki Y; Kubota K
Ann Surg Oncol; 2012 Oct; 19(11):3422-31. PubMed ID: 22576063
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of serum p53 antibody according to KRAS status in metastatic colorectal cancer patients.
Daitoku N; Miyamoto Y; Sakamoto Y; Tokunaga R; Hiyoshi Y; Nagai Y; Iwatsuki M; Iwagami S; Yoshida N; Baba H
Int J Clin Oncol; 2020 Apr; 25(4):651-659. PubMed ID: 31834556
[TBL] [Abstract][Full Text] [Related]
29. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients.
Nakagoe T; Sawai T; Tsuji T; Jibiki MA; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K
Hepatogastroenterology; 2003; 50(51):696-9. PubMed ID: 12828063
[TBL] [Abstract][Full Text] [Related]
30. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer.
Knychalski B; Lukieńczuk T
Pol Przegl Chir; 2012 Feb; 84(2):86-92. PubMed ID: 22487741
[TBL] [Abstract][Full Text] [Related]
31. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients.
Toiyama Y; Miki C; Inoue Y; Okugawa Y; Tanaka K; Kusunoki M
Int J Cancer; 2009 Oct; 125(7):1657-62. PubMed ID: 19569242
[TBL] [Abstract][Full Text] [Related]
32. [Clinical significance of serum anti-p53 antibody measurement for colorectal cancer].
Kuwabara K; Kumamoto K; Ishibashi K; Ohsawa T; Kumagai Y; Baba H; Tsuji Y; Haga N; Ishida H
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2167-9. PubMed ID: 23268012
[TBL] [Abstract][Full Text] [Related]
33. [Serum anti-p53 antibodies and CEA in monitoring of recurrences of colorectal cancer].
Bielicki D; Sulzyc-Bielicka V; Domagała W
Ann Acad Med Stetin; 2008; 54(3):99-104. PubMed ID: 19839520
[TBL] [Abstract][Full Text] [Related]
34. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.
Sakamoto Y; Miyamoto Y; Beppu T; Nitta H; Imai K; Hayashi H; Baba Y; Yoshida N; Chikamoto A; Baba H
Anticancer Res; 2015 Apr; 35(4):2359-68. PubMed ID: 25862901
[TBL] [Abstract][Full Text] [Related]
35. Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases.
Peltonen R; Österlund P; Lempinen M; Nordin A; Stenman UH; Isoniemi H
Tumour Biol; 2018 Jan; 40(1):1010428317752944. PubMed ID: 29378497
[TBL] [Abstract][Full Text] [Related]
36. Prediagnostic Antibodies to Serum p53 and Subsequent Colorectal Cancer.
Teras LR; Gapstur SM; Maliniak ML; Jacobs EJ; Gansler T; Michel A; Pawlita M; Waterboer T; Campbell PT
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):219-223. PubMed ID: 29254936
[No Abstract] [Full Text] [Related]
37. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level.
Park IJ; Choi GS; Lim KH; Kang BM; Jun SH
Ann Surg Oncol; 2009 Nov; 16(11):3087-93. PubMed ID: 19629600
[TBL] [Abstract][Full Text] [Related]
38. Detection of serum anti-P53 antibodies from patients with colorectal cancer in China using a combination of P53- and phage-ELISA: correlation to clinical parameters.
Wu J; Qiu T; Pan P; Yu D; Ju Z; Qu X; Gao X; Mao C; Wang L
Asian Pac J Cancer Prev; 2011; 12(11):2921-4. PubMed ID: 22393964
[TBL] [Abstract][Full Text] [Related]
39. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
[TBL] [Abstract][Full Text] [Related]
40. Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor.
Abdel-Aziz MM; Lotfy M; El-Kady IM; Abozaid M
Cancer Detect Prev; 2009; 32(4):329-35. PubMed ID: 16632243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
